All posts by medical

Biochemistry

Coronavirus threat to global Automatic Biochemistry Analyzers Market Future Need Assessment 2049 Cole Reports – Cole of Duty

The report on the Automatic Biochemistry Analyzers market provides a birds eye view of the current proceeding within the Automatic Biochemistry Analyzers market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Automatic Biochemistry Analyzers market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Automatic Biochemistry Analyzers market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

The Automatic Biochemistry Analyzers market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Automatic Biochemistry Analyzers market and the trends that will prevail in this industry.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2637505&source=atm

What pointers are covered in the Automatic Biochemistry Analyzers market research study?

The Automatic Biochemistry Analyzers market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Automatic Biochemistry Analyzers market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Automatic Biochemistry Analyzers market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

Market Segment AnalysisThe research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by TypeFloor-standingBench-top

Segment by ApplicationPrimary HospitalProvincial HospitalPrefectural Hospital

Global Automatic Biochemistry Analyzers Market: Regional AnalysisThe report offers in-depth assessment of the growth and other aspects of the Automatic Biochemistry Analyzers market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Automatic Biochemistry Analyzers Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2637505&source=atm

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Automatic Biochemistry Analyzers market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Automatic Biochemistry Analyzers market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Automatic Biochemistry Analyzers market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2637505&licType=S&source=atm

Some of the Major Highlights of TOC covers:

See more here:
Coronavirus threat to global Automatic Biochemistry Analyzers Market Future Need Assessment 2049 Cole Reports - Cole of Duty

Immunology

Outlook on the Artificial Immune Modulation Therapy Market to 2026 – Opportunity & Clinical Trials Insight – ResearchAndMarkets.com – Yahoo…

The "Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

The research report provides comprehensive insight on the applications of artificial immune modulation therapy in today's cancer centric treatment methodologies. This report is focused towards introducing the therapy and the cells that are contributing to the therapy in an elaborated way. The report also discusses the successful pre-clinical stage results of the therapy and information about its entry in the clinical trial landscape. The research report gives information about the growing interest of the researchers as well as companies towards the possible achievements that the therapy will face in the next few years.

Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026 Report Highlights:

Artificial Immune Modulation (AIM) is among the novel immunotherapy technologies that have been developed keeping in view the rising cases of cancer at a global level. As every immunotherapy technology focuses on one major part of the immune system, AIM technology's working is also based on artificial antigen-presenting cells (aAPC). AIM technology includes the engineering and administrating artificial antigen-presenting cells to the patients which further is projected to mimic the core functions of natural antigen-presenting cells present inside the human body.

The primary purpose with which artificial antigen-presenting cells are administered to the patient involves antigen-specific recognition signal delivery by Major Histone Compatibility molecule loaded with an antigen peptide and also a co-stimulatory signal to direct action by the T cells. Development of another immunotherapy-based treatment has caused an expansion of the field, where the contribution of immune cells against diseases is increasing exponentially. Targeting immune cells have projected a novel and regulated version of interaction between the diseased cells and the immune system.

An important aspect of AIM therapy is that it provides satisfying nature for reinforcing the working mechanism of the immune system against one target which includes the activation of specific types (antigen-presenting cells and T-cells) in order to evoke a powerful immune response against a specific antigen. It has been a few decades since the development of immunotherapy for diseases in which the immune system gets artificially activated, but few years since the discovery of AIM. Therefore, adding one more novel technology to this incredibly increases the access of eradicating cancer and other deadly cells from the body.

As per the research findings for analyzing the growing trends of artificial immune modulation, it has been observed that the therapy is prominent towards showing data that is dominant. As the other immunotherapy products that are available for cancer such as Kymriah and Yescarta and their sales record establishes a hope that the arrival of novel products under AIM therapy will also establish a market that will be more inclined towards AIM. The growing cancer cases and the poor survival rate of other cancer therapies are driving the research world a little more dominant towards AIM.

Key Topics Covered:

1. Artificial Immune Modulation Nanotechnology Overview

2. Role of Nanotechnology in Enriching Artificial Immune Modulation Platform

2.1 Nanoparticles Contributing to Other Immunotherapies Efficiency

2.2 Benefits Associated with Combining Nanotechnology to Artificial Immune Modulation

3. Synthetic Immunology to Engineer Antigen Presenting Cells

3.1 Synthetic Immunology for Already Available Immunotherapy

3.2 Eligibility & Applications of Synthetic Immunology in Artificial Immune Modulation

4. Artificial Immune Modulations for Various Indications

4.1 Immunity - Cancer Cycle Relationship

4.2 Influence of Artificial Immune Modulation Over Cancer

4.3 Influence of Artificial Immune Modulation Against Other Indications

5. T-Cell Enrichment & Expansion (E+E) Technology for Proprietary Artificial Immune Modulation Platform

6. NexImmune Clinical Trials for Artificial Immune Modulation Products

6.1 NEX-001 & NEX-003 for Acute Myeloid Leukemia

6.1.1 Overview

Story continues

6.1.2 Clinical Insight

6.2 NEX-002 for Multiple Myeloma

6.2.1 Overview

6.2.2 Clinical Insight

7. Recent Trends & Opportunities Available for Expansion of Artificial Immune Modulation Therapy

7.1 Globe Cancer Statistics

7.2 Increasing Popularity of Immunotherapy Treatments

7.3 High Adaptability by Pharmaceutical Companies

7.4 Immunotherapy in Combination with Other Cancer Treatment Methods

8. Estimated Commercial Opportunity for Artificial Immune Modulation Drugs

8.1 Immunotherapies & Price Study for Estimating Artificial Immune Modulation Products Commercial Success

8.1.1 CAR-T Cell Therapy & their Products

8.1.2 Tumor-Infiltrating Lymphocyte Immunotherapy

8.2 AIM Therapy Price Estimates

9. Drivers & Challenges Triggered with the Outcome of Artificial Immune Modulation

9.1 Drivers for Artificial Immune Modulation

9.2 Challenges for Artificial Immune Modulation

10. Future Directions for Artificial Immune Modulation

10.1 Exploring New Avenues for Immunotherapy

10.2 Future Regional Landscape for Artificial Immune Modulation

11. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/5p3pd5

View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005450/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See original here:
Outlook on the Artificial Immune Modulation Therapy Market to 2026 - Opportunity & Clinical Trials Insight - ResearchAndMarkets.com - Yahoo...

Immunology

Following the (Drug) Money – Project On Government Oversight

In an email to POGO, an aide to Murray sent a quote from the American Academy of Pediatrics (AAP) and said the group approved this quote specifically for use in your story. In the quote, Mark Del Monte, chief executive officer of the group, commended Alexander, Murray, and other lawmakers for their commitment to getting this longstanding priority across the finish line.

The CARES Act at last gives FDA the authority to safeguard public health; children will be much better off as a result, Del Monte added.

The American Academy of Pediatrics lists corporate relationships with companies such as Johnson & Johnson and GlaxoSmithKline. The organization lists in its President's Circle$50,000 and abovePampers, which is part of Procter & Gamble, maker of Pepto-Bismol and other drugstore products.

On its website, on a page titled Corporate and Organizational Partners, the American Academy of Pediatrics thanks those and other companies for their support of the Friends of Children Fund.

Through an annual membership contribution to the Fund, these companies are invited to a Corporate Summit held each summer at the AAP National Headquarters in Itasca, IL, the page says.

In response to an email from POGO, a spokesperson for the American Academy of Pediatrics, Jamie Poslosky, confirmed the quote that the Murray aide had provided. The spokesperson did not answer follow-up questions about the organizations corporate relationships.

The American Academy of Allergy, Asthma & Immunology is also a medical professionals group. In an unsigned email to POGO, the academy said its advocacy process is wholly independent, and not subject to influence by the corporate sponsors of our educational programs.

The American Academy of Allergy, Asthma & Immunology lists corporate funders such as Sanofi and GlaxoSmithKline.

Sanofis over-the-counter products include Rolaids, Selsun Blue, Aspercreme, and Dulcolax.

GlaxoSmithKline markets a variety of over-the-counter products, including Tums and Excedrin, and calls itself the number one over-the-counter respiratory medicine company.

Originally posted here:
Following the (Drug) Money - Project On Government Oversight

Immunology

Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer – GlobeNewswire

SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc.(Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Noreen R. Henig, MD as its Chief Medical Officer. As an integral member of the Companys Executive Leadership team, Dr. Henig will oversee all aspects of the Companys clinical development, regulatory and medical affairs.

Noreen brings with her a depth and breadth of expertise in clinical practice, translational science, clinical development, and medical affairs, and we are thrilled to welcome her to the Kezar team, said John Fowler, Kezars Chief Executive Officer. Her proven leadership skills, deep understanding of immunology and rare diseases, and profound appreciation of the patient voice will make a significant impact, and I look forward to working in partnership with her as we continue to advance our novel therapies for a wide range of autoimmune diseases and cancers.

Noreen Roth Henig, M.D. is a seasoned leader whose career spans clinical practice, academic medicine, translational science, clinical development, medical and regulatory affairs. She currently serves on the Board of Avidity Biosciences and most recently served as Chief Medical Officer of Breath Therapeutics, which was acquired by Zambon SpA in 2019. As CMO, Dr. Henig built and led the clinical team and was responsible for all development activities including clinical and non-clinical science, clinical operations, regulatory, project management, and medical affairs. Prior to joining Breath, Dr.Henig was Chief Medical Officer at ProQR Therapeutics where she brought two unique RNA oligonucleotides through early clinical trials in rare diseases. Before ProQR, Dr. Henig spent 2008 through 2014 at Gilead Sciences where she held roles with increasing responsibility, including building and leading a global medical affairs organization, strategic development of clinical trials Phase2-4, regulatory strategy, corporate development, leadership of key alliances and commercial strategy. Prior to joining industry, Dr. Henig spent nearly 10 years in leadership roles within academic medicine at Stanford University and California Pacific Medical Center. She is a board-certified physician in Pulmonary, Critical Care and board eligible in Allergy and Immunology. Dr.Henig received her B.A. from Yale University and her M.D. from Albert Einstein College of Medicine of Yeshiva University in 1991 with a distinction in immunology. She trained in Internal Medicine at University of California, San Francisco and in Pulmonary/Critical Care and Allergy/Immunology at University of Washington, Seattle.

I am excited to join Kezar at such an important time in the companys growth, said Dr. Henig. Kezars scientific excellence in protein homeostasis via protein degradation and secretion presents tremendous opportunity to create elegant therapies for those living with serious and often debilitating diseases. It will be a joy to work alongside Kezars talented and dynamic team to realize our full potential by combining science with innovative approaches to development and patient engagement.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, Kezar has nominated KZR-261 as its first clinical candidate for the treatment of cancer from its protein secretion program and is undergoing IND-enabling activities for the program. For more information, visit http://www.kezarlifesciences.com.

CONTACT:Celia EconomidesSVP, Strategy & External Affairsceconomides@kezarbio.com

Read the original here:
Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer - GlobeNewswire

Immunology

Anti-rheumatism drug could help those with severe COVID-19 signs : The Asahi Shimbun – Asahi Shimbun

An immunosuppressive drug for rheumatism shows encouraging signs of inhibiting severe pneumonia symptoms caused by COVID-19, researchers say.

Some patients severely affected by the new coronavirus underwent an improvement in their condition at a hospital in Osaka Prefecture after they were administered Actemra, also known as tocilizumab, which is used to treat rheumatoid arthritis.

Actemra is designed to inhibit the activity of a cytokine protein called interleukin-6 (IL-6) that is associated with the immune system. It was discovered by Tadamitsu Kishimoto, a specially appointed professor of immunology at Osaka University, and his team.

When IL-6 becomes overactive, it triggers a phenomenon known as a cytokine storm where fever, hypoxia and other problems emerge, occasionally resulting in fatal shock or multiple organ failure. Cytokine storms are believed to contribute to serious coronavirus cases.

China and other countries started administering Actemra for COVID-19 patients, and one report said 19 of 20 people treated with the drug regained their health.

In an article released in early April, a team of researchers primarily attached to the University of Toronto in Canada said coronavirus patients with a significantly high level of IL-6 develop severe conditions more easily and that Actemra is helpful in treating serious symptoms.

The team pointed out that the safety and effectiveness of the immunosuppressive drug need to be evaluated through large-scale clinical trials.

The article, which had yet to undergo a peer review, comprehensively analyzed eight reports, including theses that have yet to be examined by referees for assessment.

At the Osaka Habikino Medical Center in Habikino, Osaka Prefecture, a virus therapy team headed by infectious disease specialist Takayuki Nagai tested Actemra on seven patients with severe pneumonia.

An improvement of symptoms was reported in five of the test subjects as of April 13, although the health condition of the remaining two patients deteriorated.

The patients were carefully screened on the basis of inflammation test results, progress of symptoms and the degree of hypoxia because Actemra has not been approved for use in treating pneumonia.

"Our next step is to figure out when to start administering the drug so as to maximize its effect, said Toshio Tanaka, deputy director of the medical center.

Kishimoto, who discovered IL-6, said he believes controlling cytokine storms to allow a patients immune system to work properly will help those infected with the virus to recover from the disease.

Actemra does not eliminate the virus, but it may help save the lives of patients, he said.

Pharmaceutical companies are forging ahead with plans for clinical trials to confirm the effectiveness and safety of the drug in the context of coronavirus treatment.

The Swiss-based Roche Group announced in March it will begin a clinical trial of Actemra, covering 330 patients across the world.

Chugai Pharmaceutical Co., which released Actemra as Japans first antibody drug, is also planning a clinical study in Japan.

Go here to see the original:
Anti-rheumatism drug could help those with severe COVID-19 signs : The Asahi Shimbun - Asahi Shimbun

Cell Biology

Scientists are exploring to find the ‘Achilles heel’ of coronavirus – News-Medical.Net

Coronavirus, or more exactly SARS-CoV-2, has the world in its grip. How does the virus manage to bind to cells in the human body? How does it gain entry to the cell? How does it hijack the cell's machinery to make it help to replicate the viral genome?

Scientists around the world are working hard to answer these questions. They hope to discover the 'Achilles heel' of the virus as a target for new drugs to block the replication cycle of SARS-CoV-2. Although scientists already know a lot about the virus they still lack detailed knowledge in many areas.

Andrea Thorn and her team aim to provide these missing details. Together they form the "Coronavirus Structural Task Force" - an international network of experts in the field of structural biology.

Their goal is to validate our existing knowledge of the molecular structures of coronavirus and to fill knowledge gaps - or as she puts it: "To get the as much as possible out of the data".

Dr. Thorn, how large are the gaps in our knowledge about the coronavirus that is causing the current pandemic? "Unfortunately, much is still unknown. We are still in the dark about many things that happen at the atomic level.

However, we do know, for example, that the viral genome encodes 28 proteins that fulfill different tasks when attacking the host cell. They suppress the immune system or reprogram the cell to replicate the virus.

But we only know the structures of about half of these 28 proteins - and molecular structures are crucial in identifying and developing potential drug targets. In addition, the virus interacts with around 150 other proteins from the host cell, but we know very little about these interactions."

As their name suggests, structural biologists work to decipher and visualise the exact structure of large biological molecules, such as proteins, at the atomic level.

The synchrotron measurements they use do not produce images in the traditional sense. Instead they deliver huge amounts of data, and it is the job of the structural biologists to create three-dimensional molecular models from these data.

Bioinformaticians and computational chemists can then use computers to virtually screen these structures against thousands of substances to look for potential active agents that could bind to the respective molecules and block them. In addition, scientists use the structures to draw conclusions about the function of the proteins, for example, how they infect host cells.

Research in this field is gaining momentum as the novel coronavirus continues to spread. Each week, Andrea Thorn and her team are supplied with information about new structures which they computationally. At the same time, they sift through existing data, check their validity or improve existing structural solutions.

Coronaviruses, and the SARS virus in particular, are not new discoveries. In 2002/2003, a SARS virus triggered a pandemic that killed almost 800 people worldwide. After the number of new infections had decreased significantly in the summer of 2003, the WHO declared the pandemic over on 19 May 2004.

Dr. Thorn, the coronavirus we are dealing with today is not entirely new. Is this advantageous for your work?

"The two SARS coronaviruses are actually very similar in their genome and molecular structures. The fact that the progression of the disease and spread are so fundamentally different is due to their subtle differences. So, we are working hard to identify those differences at the structural level. Unfortunately, SARS virus research was cut back again after the pandemic ended 15 years ago. If the research activities had been continued, we might already have an effective drug for treatment available today."

Andrea Thorn wants to research such a drug in the near future. Together with colleagues from Lbeck and Berlin, she has applied to the Federal Ministry of Education and Research for funding.

The team has its focus on one particular protease - an enzyme from the coronavirus that enables replication in the host cell. The scientists hope that drug screening will help them identify a substance that inhibits this protease. This would prevent the virus from making more copies of itself.

Andrea Thorn cannot say when the coronavirus pandemic will be over. But she has a clear picture of what the future after the coronavirus crisis will look like from a scientific point of view:

"Already in the few weeks since the task force was established, we have seen the different working groups band together. Structural biologists and modelling experts have come together to build a new knowledge base and to improved their methods. These experiences can be transferred to future projects."

Andrea Thorn studied Molecular Science at the University of Erlangen and subsequently earned her doctorate at the University of Gttingen.

Her academic career has taken her to Cambridge, Oxford and the University of Hamburg. Since 2019, she has been an associate group leader at the Rudolf Virchow Center of the University of Wrzburg as part of Professor Hermann Schindelin's research group. Her group develops methods and software to extract structures from experimental data.

Andrea Thorn launched the Coronavirus Structural Task Force shortly after the World Health Organization (WHO) declared the new coronavirus a pandemic. Using the combined knowledge and skills of structural biology, she wants to help stop the virus.

See the original post here:
Scientists are exploring to find the 'Achilles heel' of coronavirus - News-Medical.Net

Cell Biology

Protein Assay Market 2020: Reporting And Evaluation Of Recent Industry Developments 2027 – Cole of Duty

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life science Industry, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Protein Assay market globally. This report on Protein Assay market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @https://www.theinsightpartners.com/sample/TIPHE100001172/

Protein assay is a method used for quick and inexpensive method to detect the concentration of proteins. Protein assays are among the widely used methods in the field of life science research. Estimating protein concentration is an essential part in electrophoresis, cell biology, protein purification, molecular biology, and various other research applications. Protein assay works mostly on the principle of color change i.e. colorimetric assay and use of standard protein such as bovine serum albumin (BSA) or immunoglobulin G (IgG)

Presence of various established market players and rising investment in the field of biotechnological and pharmaceutical R&D activities is considered to propel the growth of the market in the future years. Emerging applications of protein assay along with rise in demand for cost effective methods for clinical diagnosis is expected to provide required opportunity for growth in the market during the forecast period.

Key Players

The report also includes the profiles of key Protein Assay manufacturing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last three years, key development in past three years. Some of the key players influencing the market are Thermo Fisher Scientific Inc., PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Promega Corporation, Merck KgaA, GENERAL ELECTRIC, Lonza, BioVision Inc., Cell Signaling Technology, Inc., and CYTOSKELETON, INC. among others.

The research provides answers to the following key questions:

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Protein Assay market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal according to different segments. The report also predicts the influence of different industry aspects on the Protein Assay market segments and regions.

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPHE100001172/

Protein Assay Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Continue reading here:
Protein Assay Market 2020: Reporting And Evaluation Of Recent Industry Developments 2027 - Cole of Duty

Cell Biology

Hyd centre to grow virus in human cells for in vitro testing – Hindustan Times

New Delhi: The Hyderabad-based Centre for Cellular and Molecular Biology (CCMB) will attempt to grow SARS-CoV-2 in human cell lines, enabling in vitro ( literally, in a test tube) testing of potential drugs and vaccines against Covid-19. Experts said this could expedite testing of new drugs that have not been tried on humans before.

According to a statement from the Science and Technology ministry on Tuesday, CCMB will partner with cell therapy company, Eyestem Research Private Limited to develop these cell lines. The research team will use Eyestems human lung epithelial cell culture system provided as part of its anti-covid screening (ACS) platform to understand the molecular and pathological characteristics of SARS-CoV-2.

Culturing the virus outside the human host is a technological challenge that needs to be overcome. Eyestems cell culture system expresses the ACE2 receptor (an enzyme the Sars-Cov-2 virus uses to enter the body) and other genes that are key determinants of viral entry and replication. We hope that employing this system will allow the CCMB team to grow the virus predictably and thereby open up the potential for the drug screening and vaccine development strategies, said Dr Rakesh Mishra, Director, CCMB.

Before human trials new drugs should be tested in vitro and then in animals, said Dr Shobha Broor, former head of the department of virology at the All India Institute of Medical Sciences. For the re-purposed drugs being tried for Covid 19, there is some evidence in vitro because they have been tried for other viruses. For different viruses, different cell lines are need for testing efficacy. If we establish this system of testing Covid 19 drugs, whenever we have a new drug it can be tested quickly in the human lung epithelial cell line, she added.

In another statement, the ministry said Institute of Genomics and Integrative Biology (CSIR-IGIB) and Tata Sons have signed an agreement for licensing know-how for a paper strip based test named Feluda for rapid diagnosis of Covid 19.

Dr Anurag Agrawal, Director-IGIB said the technology was conceived and developed at CSIR IGIB and utilizes an indigenously developed cutting edge CRISPR Cas9 technology to specifically recognize the Covid 19 sequence in a sample. A combination of CRISPR biology and paper-strip chemistry leads to a visible signal readout on a paper strip that can be rapidly assessed for establishing the presence of viral infection in a sample. The test is named after Satyajit Rays fictional detective Feluda.

See the article here:
Hyd centre to grow virus in human cells for in vitro testing - Hindustan Times

Cell Biology

Adoption of Human Platelet Lysate Market Through COVID-19 Pandemic to Increase Across Top Countries in the Globe IN the Coming Years – Cole of Duty

Rising funding for research & development activities, increasing number of research centers, and growing partnerships between research centers, biotechnology companies, and academic institutes for basic research are the prominent driving factors for the growth of thehuman platelet lysate market.

Also, increasing demand for animal-free serum media is a key catalyzer for the growth of the human platelet lysate market. Human platelet lysates, a growth supplement for in-vitro cell culture, are a suitable alternative to fetal bovine serum, and expected to find application in various therapeutics. The global human platelet lysate market is set to progress at a decent CAGR of around 4% over the period of 2019 to 2029.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/16789

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/16789

Key Takeaways from Human Platelet Lysate Market Study

Manufacturers can focus on developing countries such as India that offer significant gains in terms of revenue, through the sale of human platelet lysates at an economical cost,says a PMR analyst.

Increase in Life Science Research Funding

Various government, private, and commercial organizations are focused on increasing research & development activities for continuous innovation in the field of life sciences. These organizations provide funds for ongoing research projects and pipeline products. In 2013, around 59% of total research & development expenditure in the U.S. was from federal funding agencies. In 2016, the National Institute of Health reported investments of nearly US$ 1.4 Bn toward stem cell research in the field of cell biology and electrical engineering.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/16789

Want More Insights?

A new report by Persistence Market Research provides unparalleled insights on the evolution of the human platelet lysate market during 2014-2018, and presents demand projections for 2019-2029, on the basis of product type (heparin-free platelet lysates and human platelet lysates with heparin), application (research use and clinical use), and end user (academic and research institutes, biopharmaceutical companies, and other applications), across various prominent regions (North America, Latin America, Europe, East Asia, South Asia. Oceania, and MEA).

Go here to read the rest:
Adoption of Human Platelet Lysate Market Through COVID-19 Pandemic to Increase Across Top Countries in the Globe IN the Coming Years - Cole of Duty

Cell Biology

aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine – BioSpace

Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference

Findings confirm that aTyrs lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflammatory conditions

SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma Inc. Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that two abstracts originally accepted for presentation at the 2020 ATS International Conference will be published in the ATS journal, American Journal of Respiratory and Critical Care Medicine. One abstract characterizes the molecular basis for ATYR1923s immunomodulatory properties, including its ability to specifically and selectively bind to NRP2, a target that has been implicated in a broad range of immune-mediated diseases. The second abstract demonstrates that NRP2 is expressed on key immune cells in inflammatory conditions, including sarcoidosis granulomas, reinforcing its status as a key target in the treatment of immune-mediated diseases.

We are very pleased to have these abstracts, which were originally accepted for presentation at the ATS International Conference, published in the highly-regarded American Journal of Respiratory and Critical Care Medicine, stated Dr. Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. The findings summarized in these abstracts confirm the significant role of NRP2 in serious inflammatory diseases, and further elucidate the mechanism of action of ATYR1923 in its ability to selectively bind to this unique target. We look forward to final results from our ongoing Phase 1b/2a clinical trial of ATYR1923 in patients with pulmonary sarcoidosis while in parallel leveraging our numerous research collaborations with biopharmaceutical leaders and academia to further expand our pre-clinical pipeline.

Details of the abstracts are as follows:

P1173 - ATYR1923 Specifically Binds to Neuropilin-2, a Novel Therapeutic Target for the Treatment of Immune-Mediated DiseasesNeuropilin-2 (NRP2) is a pleiotropic cell surface receptor known to be expressed on a number of different immune cell types that plays a key role in regulating inflammatory responses. aTyr Pharmas lead clinical candidate, ATYR1923, is a fusion protein combining a novel immunomodulatory domain from histidyl-tRNA synthetase (HARS) and a human IgG1 Fc. ATYR1923 has previously demonstrated potent immunomodulatory activity in vitro and in vivo. ATYR1923 specifically and selectively binds to NRP2 on the cell surface, which was discovered by cell microarray screening and confirmed by surface plasmon resonance (SPR) and also by flow cytometry analysis of HEK293 cells over-expressing NRP2. Furthermore, ATYR1923 was also found to bind to cells that endogenously express NRP2 on the surface (such as THP-1 polarized M1 macrophages). These findings indicate that modulation of the NRP2 signaling pathway could be a novel therapeutic approach to immune-mediated diseases. ATYR1923 is currently being evaluated in a Phase 1b/2a study in patients with pulmonary sarcoidosis, an inflammatory disease which can result in lung fibrosis.

P983 - Neuropilin-2, the Specific Binding Partner to ATYR1923, Is Expressed in Sarcoid Granulomas and Key Immune CellsaTyr reports for the first time that NRP2 is expressed in samples obtained from lung and skin of sarcoidosis patients. More specifically, NRP2 expression was readily detectable within the granulomas in both skin and lung samples. In this abstract, the company demonstrates that NRP2 expression can be detected on key immune cells known to play an important role in inflammation and granuloma formation. These findings highlight the potential of ATYR1923 to exert its effect on various immune cells directly related to the pathology of the target patient population.

About ATYR1923

aTyr is developing ATYR1923 as a potential therapeutic for patients with interstitial lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr is currently enrolling a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923.

About NRP2

Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses. In many forms of cancer, high NRP2 expression is associated with worse outcomes. NRP2 can interact with multiple ligands and co-receptors through distinct domains to influence their functional roles, making it a potential drug target with multiple distinct therapeutic applications. NRP2 interacts with type 3 semaphorins and plexins to impact inflammation and with forms of vascular endothelial growth factor (VEGF) and their receptors, to impact lymphangiogenesis. In addition, NPR2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs. aTyr is currently investigating NRP2 receptor biology, both internally and in collaboration with key academic thought leaders, as a novel target for new product candidates for a variety of diseases, including cancer and inflammation.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit http://www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, include statements regarding the potential therapeutic benefits and applications of our product candidates; our ability to successfully advance our product candidates, undertake certain development activities (such as the initiation of clinical trials, clinical trial enrollment, the conduct of clinical trials and the announcement of top-line results) and accomplish certain development goals, and the timing of such events; and the scope and strength of our intellectual property portfolio. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility of unexpected expenses or other demands on our cash resources, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Go here to see the original:
aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine - BioSpace